SAN FRANCISCO , June 23, 2022 /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled “Genome Editing/Genome Engineering – Global Market Trajectory & Analytics”. The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace.
FACTS AT A GLANCE
What’s New for 2022?
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies – Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to our digital archives and MarketGlass Research Platform
- Complimentary updates for one year
Edition: 9; Released: January 2022
Executive Pool: 3437
Companies: 27 – Players covered include CRISPR Therapeutics AG; Editas Medicine, Inc.; GenScript Biotech Corporation; Horizon Discovery Group PLC; Integrated DNA Technologies (IDT), Inc.; Lonza Group AG; Merck & Co., Inc.; New England Biolabs, Inc.; OriGene Technologies, Inc.; Sangamo Therapeutics; Thermo Fisher Scientific, Inc.; Transposagen Biopharmaceuticals, Inc. and Others.
Coverage: All major geographies and key segments
Segments: Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering, Other Applications); Technology (CRISPR, TALEN, ZFN, Other Technologies)
Geographies: World; United States; Canada; Japan; China; Europe …
